Secondary endpoints in the MINDFuL trial include the CDR-SB, E-Cog, ADL and Neuropsychiatric Inventory (NPI) instruments, along with blood biomarker and neuroimaging outcomes. Baseline demographics, ...
A study conducted by Prof. Thai-Yen Ling at National Taiwan University underscores the potential of small extracellular ...
Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has entered into the Medicaid ...
The following is a summary of “A Novel Molecular Regulatory Network in Bone Marrow Mesenchymal Stem Cells for Age-Related Osteoporosis,” published in the March 2025 issue of Clinical Endocrinology by ...
HotCopper on MSN1d
Mesoblast kicks off treatment for first 3 kids with graft-host disease. So why are shares down?HotCopper favourite Mesoblast (ASX:MSB) has begun treating the first three children with skin graft-versus-host disease in ...
Mesoblast’s RYONCIL ® (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA approved mesenchymal ...
Mesoblast (MSB:ASX; MESO:Nasdaq) has secured a significant agreement with the U.S. Centers for Medicare & Medicaid Services ...
Aged individuals and astronauts experience bone loss despite rigorous physical activity. Bone mechanoresponse is in-part ...
Scientists have unveiled a revolutionary method for mass-producing high-quality human mitochondria, potentially transforming ...
Experts explain how they work, and how they can be incorporated topically into your routine to make skin look healthier, ...
Q4 2024 Earnings Call Transcript March 27, 2025 BioRestorative Therapies, Inc. beats earnings expectations. Reported EPS is $ ...
Human extracellular matrices can be edited in their composition using the CRISPR/Cas9 system, leading to materials exhibiting tailored regenerative capacities.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback